Apremilast (CAS 608141-41-9): A Comprehensive Product Introduction
Apremilast, with the CAS number 608141-41-9, is a remarkable pharmaceutical compound that has gained significant attention in the medical and research fields. This article aims to provide a detailed and in – depth introduction to Apremilast, covering its properties, uses, applications in various fields, and the preparation methods.
Properties of Apremilast
Apremilast is a small – molecule phosphodiesterase 4 (PDE4) inhibitor. Chemically, it has a specific molecular structure that contributes to its unique pharmacological properties. The molecular formula of Apremilast is \(C_{22}H_{24}N_{2}O_{7}\), and its molecular weight is approximately 428.43 g/mol. It appears as a white to off – white crystalline powder. In terms of solubility, it has certain solubility characteristics in different solvents. It is sparingly soluble in water, which is an important factor to consider in its formulation and administration. Apremilast is stable under normal storage conditions, but like many pharmaceutical compounds, it should be stored in a cool, dry place away from light to maintain its stability.
Uses of Apremilast
One of the primary uses of Apremilast is in the treatment of certain inflammatory diseases. It has been approved by regulatory authorities for the treatment of psoriasis and psoriatic arthritis. In psoriasis, Apremilast works by modulating the immune response. Psoriasis is an autoimmune – mediated skin disease characterized by excessive proliferation of keratinocytes and inflammation. By inhibiting PDE4, Apremilast reduces the production of pro – inflammatory cytokines such as tumor necrosis factor – alpha (TNF – α), interleukin – 23 (IL – 23), and interleukin – 17 (IL – 17). These cytokines play crucial roles in the pathogenesis of psoriasis. As a result, Apremilast can improve the symptoms of psoriasis, including reducing skin redness, scaling, and itching.
For psoriatic arthritis, Apremilast also has a beneficial effect. Psoriatic arthritis is a chronic inflammatory arthritis that occurs in some patients with psoriasis. It can cause joint pain, swelling, stiffness, and damage to the joints. Apremilast helps to control the inflammation in the joints by interfering with the PDE4 – mediated signaling pathways. This leads to a reduction in joint symptoms and an improvement in the overall quality of life for patients with psoriatic arthritis.
In addition to these approved uses, Apremilast is also being investigated for its potential in treating other inflammatory and autoimmune diseases. Some pre – clinical and clinical studies are exploring its use in diseases such as Behçet’s disease, atopic dermatitis, and multiple sclerosis. The anti – inflammatory and immunomodulatory properties of Apremilast make it a promising candidate for these conditions.
Applications in Various Fields
Medical Field
In the medical field, Apremilast is mainly used as a therapeutic agent. Dermatologists prescribe Apremilast to patients with moderate to severe psoriasis who are candidates for systemic therapy. The oral administration of Apremilast provides a convenient treatment option compared to some other systemic treatments, such as injectable biologics. Rheumatologists use Apremilast in the management of psoriatic arthritis. It can be used as a monotherapy or in combination with other medications, depending on the severity of the disease and the patient’s response to treatment.
Research Field
In the research field, Apremilast is a valuable tool for studying the role of PDE4 in inflammation and immune regulation. Scientists use Apremilast in in vitro and in vivo experiments to understand the molecular mechanisms underlying its anti – inflammatory effects. It can also be used to develop new treatment strategies for various inflammatory diseases. For example, researchers may use Apremilast as a reference compound to screen for new PDE4 inhibitors with better efficacy and fewer side effects.
Pharmaceutical Industry
In the pharmaceutical industry, Apremilast is involved in the development of new drug formulations. Pharmaceutical companies are constantly looking for ways to improve the bioavailability, stability, and patient compliance of Apremilast. They may develop new dosage forms, such as extended – release tablets or oral suspensions, to optimize the treatment outcomes. Apremilast is also a key component in the production of combination therapies, where it is combined with other drugs to enhance the therapeutic effect.
Preparation Methods of Apremilast
The synthesis of Apremilast involves a series of chemical reactions. One of the common synthetic routes starts with the preparation of key intermediates. The first step usually involves the synthesis of a substituted benzamide derivative. This can be achieved through a reaction between an appropriate benzoic acid derivative and an amine in the presence of a coupling agent. The resulting benzamide intermediate is then further functionalized through a series of reactions, including alkylation, acylation, and cyclization reactions.
For example, a typical synthesis may start with the reaction of 3 – acetamido – 4 – methoxybenzoic acid with an amine to form the corresponding benzamide. This benzamide is then alkylated using an appropriate alkyl halide in the presence of a base. The alkylated product is further acylated with an acid chloride or an anhydride. After that, a cyclization reaction is carried out to form the characteristic ring structure of Apremilast. Finally, purification steps such as recrystallization or chromatography are used to obtain pure Apremilast.
It is important to note that the synthesis of Apremilast requires strict control of reaction conditions, including temperature, reaction time, and the purity of starting materials. The use of appropriate catalysts and solvents is also crucial to ensure the high yield and quality of the final product.